ESPR
Esperion Therapeutics, Inc.·Healthcare
2.04
0.488%(−0.01)
Market ClosedLast Updated: — ET
52W L: $0.6952W H: $4.18
ESPR NEWS
defenseworld.net
3d ago
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
Esperion Therapeutics (NASDAQ: ESPR) outlined its commercial progress and strategic priorities at Needham and Company's 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and guideline tailwinds for its cholesterol franchise, and the recent acquisition of Corstasis Therapeutics and its heart failure product Enbumyst. President and CEO Sheldon Koenig said the company has made significant strides
zacks.com
Apr 9
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
defenseworld.net
Apr 6
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.
JPMorgan Chase and Co. raised its stake in Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 68.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 945,491 shares of the biopharmaceutical company's stock after buying an additional 384,095 shares during the
globenewswire.com
Apr 2
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty financing agreement under which certain funds managed by Athyrium Capital Management (the “Athyrium Funds”) will acquire 100% of Esperion's royalty interest, held by Esperion pursuant to that certain License and Collaboration Agreement, dated as of April 17, 2020, as amended, by and among Esperion and Otsuka Pharmaceutical Co., Ltd (“Otsuka”), of Otsuka's net sales of bempedoic acid products in Japan from and after January 1, 2026, together with related regulatory and commercial milestone payments, subject to a cap.
globenewswire.com
Apr 2
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth –
defenseworld.net
Mar 17
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference
Executives from Esperion Therapeutics (NASDAQ: ESPR) highlighted accelerating revenue growth, plans to expand its commercial footprint, and details of a pending acquisition during remarks at the Citizens Life Sciences Conference in Miami, coming a day after the company reported earnings. 2025 results and momentum entering 2026 Chief Executive Officer Sheldon Koenig said Esperion delivered what he
